Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 3/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | ITK | Q08881 | 1/20 | 0.32 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4691771 | 0.92 | ITK (0.36) | GRM1CNR2HDAC1ITKCNR1 | |
| SCHEMBL4688812 | 0.84 | GRM1 (0.42) | GRM1CNR2ACSS2CNR1ADORA2A | |
| SCHEMBL4688569 | 0.81 | GRM1 (0.43) | GRM1HDAC1CYP2A6 | |
| SCHEMBL4693193 | 0.80 | GRM1 (0.46) | GRM1ITKACSS2ADORA2AMETTL3 | |
| SCHEMBL4688818 | 0.77 | CNR2 (0.35) | GRM1CNR2ITKCNR1ADORA2A | |
| SCHEMBL4691974 | 0.77 | GRM1 (0.39) | GRM1 | |
| Hydrochloric Acid SCHEMBL4692163 | 0.77 | GRM1 (0.39) | GRM1CNR2ITKACSS2METTL3 | |
| SCHEMBL4692387 | 0.76 | METTL3 (0.41) | GRM1CNR2ITKACSS2CNR1 | |
| Hydrochloric Acid SCHEMBL4694732 | 0.75 | METTL3 (0.40) | GRM1CNR2ITKACSS2CNR1 | |
| Hydrochloric Acid SCHEMBL4694677 | 0.73 | METTL3 (0.42) | GRM1METTL3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1486501-B1 | AMINOMETHYL-SUBSTITUTED THIAZOLOBENZIMIDAZOLE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2008-09-10 | — | — | EP | disclosed |
| US-7250429-B2 | Aminomethyl-substituted thiazolobenzimidazole compounds | ASTELLAS PHARMA INC. (JP) | 2007-07-31 | — | — | US | disclosed |
| US-20050148642-A1 | Aminomethyl-substituted thiazolobenzimidazole derivative | ASTELLAS PHARMA INC. (JP) | 2005-07-07 | — | — | US | disclosed |
| EP-1486501-A1 | AMINOMETHYL-SUBSTITUTED THIAZOLOBENZIMIDAZOLE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148642-A1 | Aminomethyl-substituted thiazolobenzimidazole derivative | GRM1, GRIN1, GRM3 | GRM1 1/4885CNR2 306/4885HDAC1 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.